Transgenic plants as factories for biopharmaceuticals

Standard

Transgenic plants as factories for biopharmaceuticals. / Giddings, Glynis; Allison, Gordon; Brooks, Douglas; Carter, Adrian .

In: Nature Biotechnology, Vol. 18, 2000, p. 1151-1155.

Research output: Contribution to journalArticle

Harvard

Giddings, G, Allison, G, Brooks, D & Carter, A 2000, 'Transgenic plants as factories for biopharmaceuticals', Nature Biotechnology, vol. 18, pp. 1151-1155. https://doi.org/10.1038/81132

APA

Giddings, G., Allison, G., Brooks, D., & Carter, A. (2000). Transgenic plants as factories for biopharmaceuticals. Nature Biotechnology, 18, 1151-1155. https://doi.org/10.1038/81132

Vancouver

Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as factories for biopharmaceuticals. Nature Biotechnology. 2000;18:1151-1155. https://doi.org/10.1038/81132

Author

Giddings, Glynis ; Allison, Gordon ; Brooks, Douglas ; Carter, Adrian . / Transgenic plants as factories for biopharmaceuticals. In: Nature Biotechnology. 2000 ; Vol. 18. pp. 1151-1155.

Bibtex - Download

@article{ff5e04620485408d8453f19ccb29d143,
title = "Transgenic plants as factories for biopharmaceuticals",
abstract = "biopharmaceutical proteins and peptides because they are easily transformed and provide a cheap source of protein. Several biotechnology companies are now actively developing, field testing, and patenting plant expression systems, while clinical trials are proceeding on the first biopharmaceuticals derived from them. One transgenic plant-derived biopharmaceutical, hirudin, is now being commercially produced in Canada for the first time. Product purification is potentially an expensive process, and various methods are currently being developed to overcome this problem, including oleosin-fusion technology, which allows extraction with oil bodies. In some cases, delivery of a biopharmaceutical product by direct ingestion of the modified plant potentially removes the need for purification. Such biopharmaceuticals and edible vaccines can be stored and distributed as seeds, tubers, or fruits, making immunization programs in developing countries cheaper and potentially easier to administer. Some of the most expensive biopharmaceuticals of restricted availability, such as glucocerebrosidase, could become much cheaper and more plentiful through production in transgenic plants.",
keywords = "biopharmaceuticals, GM crops, edible vaccine, antibodies, production systems",
author = "Glynis Giddings and Gordon Allison and Douglas Brooks and Adrian Carter",
year = "2000",
doi = "10.1038/81132",
language = "English",
volume = "18",
pages = "1151--1155",
journal = "Nature Biotechnology",
issn = "1087-0156",
publisher = "Springer Nature",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Transgenic plants as factories for biopharmaceuticals

AU - Giddings, Glynis

AU - Allison, Gordon

AU - Brooks, Douglas

AU - Carter, Adrian

PY - 2000

Y1 - 2000

N2 - biopharmaceutical proteins and peptides because they are easily transformed and provide a cheap source of protein. Several biotechnology companies are now actively developing, field testing, and patenting plant expression systems, while clinical trials are proceeding on the first biopharmaceuticals derived from them. One transgenic plant-derived biopharmaceutical, hirudin, is now being commercially produced in Canada for the first time. Product purification is potentially an expensive process, and various methods are currently being developed to overcome this problem, including oleosin-fusion technology, which allows extraction with oil bodies. In some cases, delivery of a biopharmaceutical product by direct ingestion of the modified plant potentially removes the need for purification. Such biopharmaceuticals and edible vaccines can be stored and distributed as seeds, tubers, or fruits, making immunization programs in developing countries cheaper and potentially easier to administer. Some of the most expensive biopharmaceuticals of restricted availability, such as glucocerebrosidase, could become much cheaper and more plentiful through production in transgenic plants.

AB - biopharmaceutical proteins and peptides because they are easily transformed and provide a cheap source of protein. Several biotechnology companies are now actively developing, field testing, and patenting plant expression systems, while clinical trials are proceeding on the first biopharmaceuticals derived from them. One transgenic plant-derived biopharmaceutical, hirudin, is now being commercially produced in Canada for the first time. Product purification is potentially an expensive process, and various methods are currently being developed to overcome this problem, including oleosin-fusion technology, which allows extraction with oil bodies. In some cases, delivery of a biopharmaceutical product by direct ingestion of the modified plant potentially removes the need for purification. Such biopharmaceuticals and edible vaccines can be stored and distributed as seeds, tubers, or fruits, making immunization programs in developing countries cheaper and potentially easier to administer. Some of the most expensive biopharmaceuticals of restricted availability, such as glucocerebrosidase, could become much cheaper and more plentiful through production in transgenic plants.

KW - biopharmaceuticals

KW - GM crops

KW - edible vaccine

KW - antibodies

KW - production systems

UR - http://hdl.handle.net/2160/43184

U2 - 10.1038/81132

DO - 10.1038/81132

M3 - Article

VL - 18

SP - 1151

EP - 1155

JO - Nature Biotechnology

JF - Nature Biotechnology

SN - 1087-0156

ER -

View graph of relations
Citation formats